Innovation Impact Investment advisory group

Dr Sheriff Abdullahi is the Managing Director for Singapore, Malaysia and Brunei at the global biopharmaceutical company, MSD. He is responsible for driving the commercial success of MSD’s human health business in Singapore, Malaysia and Brunei.

Since joining MSD in 2020, he has led global teams to expand access to MSD’s medicines and vaccines around the world, and improved access to MSD’s oncology medicines and vaccines across the world. He also established global centers of excellence within MSD in value-based contracting, innovative financing and customer partnerships.

Before joining MSD, Sheriff was with GE Healthcare and spent many years as a consultant in the UK, working with clients including the NHS.

He is a leader who seeks curiosity, creativity and impact from his teams. Sheriff cares deeply about helping others find ways to flourish and takes great pride in celebrating people for who they are and who they want to be.

Sheriff holds an Engineering Doctorate and a Master of Science from Loughborough University in UK. He is married and has three children. Outside of work, he enjoys reading about history and spending quality time with his family.

Connect with Sheriff on LinkedIn.

Rachel joined Macmillan’s board in September 2020 and is Global CIO at WPP, the world's leading creative transformation company. She has extensive experience of driving digital transformation through her technology career in the media, financial services and telecoms industries. Prior to her role at WPP, Rachel served in technology leadership roles at M&S Money, HSBC, ACE Group, Vodafone and BT, living and working across EMEA, Asia, North and Latin America.

A passionate diversity and inclusion champion, Rachel sponsors a number of global development programmes for women and the LGBTQ+ community. She has wide-ranging governance experience from her corporate career and being on the boards of several charities, advisory and industry bodies.

Rachel also serves as Chair of the Board of Trustees of FACT, the UK's leading digital arts charity that believes in enriching lives and shaping the future through film, art and creative technology.

Connect with Rachel on LinkedIn.

David Kaye is the founder and CEO of Puma Capital Group. He is responsible for leading their strategy to create a robust and dynamic platform on which each of their four core businesses can thrive: Puma Investments, Puma Private Equity, Puma Property Finance and Puma Public Markets.

David graduated from Oxford with a degree in law and practiced as a commercial barrister at a leading London set of chambers for five years. He specialised in advising on a range of complex commercial legal issues with a particular focus on financial investments and real estate. He joined Shore Capital Group, of which Puma Capital Group is a member, in January 2006.

Prior to joining Macmillan’s innovation impact investment advisory group, David was a long-standing volunteer member of the Macmillan Cancer Support Annual Gala committee and chaired the event for several years.

Connect with David on LinkedIn.

Dawn is a cancer survivor. She has lived experience of many of the issues that matter most to cancer and a personal goal to do whatever she can to aid in improving the diagnosis experience of other cancer patients.

In her day job, Dawn is an Associate Professor of Health Economics and Health Policy at the Peninsula Technology Assessment Group (PenTAG). PenTAG is a prestigious research unit in the UK specialising in providing expert advice on the clinical and cost-effectiveness of new diagnostics and treatments to the National Institute of Health and Care Excellence (NICE). Dawn joined PenTAG and Exeter University in September 2022, following a successful tenure as the Chief Scientific Officer at a health economics consultancy Lumanity (previously BresMed). Dawn serves as a member of NICEs Interventional Procedures Advisory Committee (IPAC).

Outside of her day job Dawn volunteers for Citizens Advice.

Connect with Dawn on LinkedIn.

Archie is a Director at True, a consumer-focused investment and advisory business. Archie supports leading corporates on innovation, strategy and venture investment activity, and leads True’s ESG and Impact initiatives.  

Archie was previously head of Business Development and Innovation at the John Lewis Partnership. He started his career across audit and strategy consulting at PwC. He has an MSci in Pharmacology from the University of Bristol and a certification from the University of Cambridge Institute for Sustainability Leadership course. 

Connect with Archie on LinkedIn.

Stringer has over 26 years of experience in health technology across various systems around the world, covering technology deployment, strategy consulting, VC investment and board roles with both startups and scale-ups. Joe most recently led the healthtech investment team at Octopus Ventures, one of the most active European venture capitalist funds. He is now a partner for a £500m family office healthtech impact fund, Exec Chair at automata.tech, a non-executive director at Holland & Barrett, and a board advisor to a number of high growth startups in the sector such as Mettle, Music Health and Ufonia.  

Before Octopus, Joe was the market leader for Google Health in the UK and Europe, the Middle East and Africa, and led the ventures and healthcare consulting practices for Ernst & Young in the UK. A firm believer in accessible and affordable healthcare for all, Joe is an active proponent and campaigner for tackling healthcare through longevity and wellbeing, including in public health, and for the last 6 years was a trustee at the UK Royal Society for Public Health (RPSH). 

Joe has two children and lives in Bath. 

Connect with Joe on LinkedIn.